Overview

* Company maintains strong cash position, funding operations through Q1 2028

* Net loss for Q3 2025 was $21.0 mln, slightly higher than Q3 2024

Outlook

* Neurogene's cash position expected to fund operations through Q1 2028

Result Drivers

* R&D expenses were $17.2 million for the three months September 30, 2025 compared to $16.3 million for the three months ended September 30, 2024.

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.99

Q3 Net -$20.95

Income mln

Q3 $23.80

Operatin mln

g

Expenses

Q3 -$23.80

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Neurogene Inc ( NGNE ) is $60.00, about 55.9% above its November 13 closing price of $26.49

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)